Pharmaceuticals

BrightGene

BrightGene released FY2026 Q1 earnings on April 29 After-Market BJT, actual revenue CNY 324.93 M, actual EPS CNY 0.02

BrightGene FY2026 Q1 Earnings Release on April 30 After-Market (BJT)

BrightGene to Release FY2025 Earnings on March 20 Pre-Market (BJT), Forecast Revenue CNY 1.444 B, EPS CNY 0.6

BrightGene released FY2025 Q4 earnings on February 27 Pre-Market (BJT), actual revenue CNY 349.39 M, actual EPS CNY 0.0122

BrightGene released FY2025 Annual Earnings on February 27 Pre-Market (BJT), Actual Revenue CNY 1.224 B (Forecast CNY 1.444 B), Actual EPS CNY 0.13 (Forecast CNY 0.6)

BrightGene released FY2025 Q3 earnings on October 30 After-Market (BJT), actual revenue CNY 336.81 M, actual EPS CNY 0.083

BrightGene released FY2025 9 Months Earnings on October 30 After-Market (BJT), actual revenue CNY 874.25 M, actual EPS CNY 0.1228

BrightGene FY2025 Q3 Earnings Release on October 31 After-Market BJT

BrightGene released FY2025 Semi-Annual earnings on August 28 After-Market (BJT), actual revenue CNY 537.44 M, actual EPS CNY 0.04

BrightGene released FY2025 Q2 earnings on August 28 After-Market (BJT), actual revenue CNY 288.48 M, actual EPS CNY 0.0098

BrightGene FY2025 Semi-Annual Earnings Release on August 29, 2025 (BJT)

Eastwu Securities Analyst Publishes Buy Rating Report on Borui Medicine

Borui Pharmaceutical and China Resources Sanjiu Enter into Collaboration Agreement for BGM0504 Injection

Eastwu Securities Gives Buy Rating to Borui Medicine

Borui Pharmaceutical plans to raise up to 500 million yuan through private placement

Shanghai Sci-Tech Innovation Board 100 Index and Sci-Tech 100ETF Huaxia Decline, NMPA Launches the 11th Batch of Pharmaceutical Concentrated Procurement

Eastwu Securities Upgrades Borui Medicine Rating to 'Buy'

Borui Medicine Warned Again for Mismanagement of Raised Funds

Approval Granted for Eltemi Tiotropium Powder for Inhalation Clinical Trials

688166

BrightGene Bio-Medical's Phase III clinical trial results for BGM0504 show significant weight loss and improvements in various metabolic parameters, including a 19.3% mean weight reduction and a 22.9 mmHg decrease in systolic blood pressure. The drug's efficacy extends beyond weight management, indicating a shift in the role of GIP from a supporting player to a key variable in metabolic regulation. This comprehensive approach highlights the potential for BGM0504 to address multiple chronic diseases simultaneously, marking a significant advancement in the weight loss drug market.

prnewswire

02:08 ETGIP Moves from Supporting Role to Key Variable: BrightGene Bio-Medical's Phase III Results Signal Differentiation in Weight Loss Arena

BrightGene Bio-Medical Technology Co., Ltd. announced positive results from a Phase III trial of its BGM0504 injection, a dual receptor agonist for weight management. The trial showed a 19.3% weight reduction and a 16.5 cm decrease in waist circumference, alongside significant reductions in blood pressure and uric acid levels. BGM0504 demonstrated strong tolerability with a low discontinuation rate. The results indicate a shift in focus from mere weight loss to comprehensive cardiometabolic benefits, positioning BGM0504 as a leading option in the competitive weight management market.

12:10 ET19.3% Weight Reduction, 16.5 cm Waist Circumference Decrease, SBP/DBP Reductions of 22.9/12.9 mmHg, 70.7 μmol/L Uric Acid Reduction, and 33.6% Triglyceride Reduction: BGM0504 Demonstrates Comprehensive Cardiometabolic Regulation Capabilities

BrightGene Bio-Medical Technology Co., Ltd. announced positive results from its Phase III trial of BGM0504, a dual receptor agonist for obesity. The trial showed a 19.3% mean weight reduction and a 16.5 cm decrease in waist circumference. Participants with hypertension experienced a mean systolic/diastolic blood pressure reduction of 22.9/12.9 mmHg. Additionally, uric acid levels decreased by 70.7 μmol/L. The treatment demonstrated favorable safety with low discontinuation rates due to adverse events. Overall, BGM0504 met its primary and secondary endpoints, indicating significant efficacy and safety in managing obesity and related conditions.

08:20 ETBGM0504 Achieves 19.3% Robust Weight Reduction, 16.5 cm Waist Circumference Decrease, Significant SBP/DBP Improvements of 22.9/12.9 mmHg, and 70.7 μmol/L Uric Acid Reduction; Phase III Trial Meets Primary Endpoint and All Key Secondary Endpoints

Borui Pharmaceutical announced that its subsidiary has successfully achieved the goals in the Phase III clinical trial for the weight loss indication of its BGM0504 injection. This dual agonist of GLP-1 and GIP receptors shows potential for treating metabolic diseases, including blood sugar control and weight loss. The BGM0504 injection is also undergoing Phase III trials for type 2 diabetes in China.

CoinLive

BGM0504 Injection Achieves Phase III Clinical Trial Goals for Weight Loss

000919

600267

002361

603698

As of the midday close on April 15, the Shanghai Composite Index rose 0.37%, the Shenzhen Component Index fell 0.25%, and the GEM Index dropped 0.23%. Innovative drug concept stocks such as BrightGene, HISUN, and JINLING PHARM. performed strongly, hitting the limit up. Commercial aerospace concepts also continued to rise, with CETEC, Hualing Cables, and SHENJIAN GUFEN all hitting the limit up. In contrast, oil and gas stocks declined, with Meineng Energy touching the limit down; the lithium battery sector adjusted, with Haikexinyuan falling more than 10%. Overall, individual stocks showed more declines than gains, with total trading volume reaching 1.59 trillion yuan

Wallstreetcn

JINLING PHARM.

HISUN

SHENJIAN GUFEN

CETEC

ChiNext

SSE Index

HUNAN VALIN WIRE&CABLE

WG Tech

Meineng Energy

Hi-Tech Spring

Shenzhen Index

April 15 Midday Market Review: GEM Index Opens High and Falls, Closing Down 0.23%; Innovative Drug Concepts Rally Collectively

BrightGene Bio-Medical Technology Co., Ltd. announced positive topline results from Phase 1 clinical studies of BGM0504, an oral GLP-1/GIP dual receptor agonist, in China and the U.S. The drug was well tolerated with no serious adverse events. Preliminary efficacy results showed body weight reductions of 1.0% to 5.6% in China and 2.7% to 8.2% in the U.S. after treatment. BGM0504 is still investigational and not approved for marketing. Further studies are needed to confirm its safety and efficacy.

02:32 ETBrightGene Announces Positive Topline Phase 1 Results of Oral BGM0504 in Obesity in China and the United States

BrightGene announced that on September 26, 2025, the company's board of directors approved the repurchase of shares through centralized bidding, intended for the employee stock ownership plan or equity incentives, with an expected repurchase amount of RMB 10 million to 20 million, and the repurchase period until September 25, 2026. As of October 31, 2025, the company had cumulatively repurchased 55,880 shares, accounting for 0.0132% of the total share capital, with a repurchase price of RMB 52.96 to 54.28 per share, and a total amount paid of RMB 2,993,933

Zhitong

BrightGene: Plans to repurchase shares worth 10 million to 20 million yuan, has repurchased nearly 3 million yuan

BrightGene announced that its revenue for the third quarter was 337 million yuan, a year-on-year increase of 5.54%; net profit was 33.1468 million yuan, a year-on-year decrease of 53.34%. Revenue for the first three quarters was 874 million yuan, a year-on-year decrease of 10.50%; net profit was 5.032 million yuan, a year-on-year decrease of 71.64%

BrightGene: Net profit in the third quarter was 33.1468 million yuan, a year-on-year decrease of 53.34%

BrightGene(688166.SH)